Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps

Respiratory Research

Volumn 12, Issue , 2011, Pages

  Bateman, Eric D ^a   Harrison, Tim W ^b   Quirce, Santiago ^c   Reddel, Helen K ^d   Buhl, Roland ^e   Humbert, Marc ^f   Jenkins, Christine R ^d   Peterson, Stefan ^g   Östlund, Ollie ^g   O'Byrne, Paul M ^h   Sears, Malcolm R ^h   Eriksson, Göran S ^g,i  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^f UNIVERSITÉ PARIS SACLAY   (France)

^g ASTRAZENECA R AND D   (Sweden)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; TERBUTALINE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; ETHANOLAMINE DERIVATIVE; FORMOTEROL; GLUCOCORTICOID;

ADULT; ARTICLE; ASTHMA; DISEASE CONTROL; DISEASE EXACERBATION; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; RETROSPECTIVE STUDY; ANALYSIS OF VARIANCE; DRUG COMBINATION; DRUG EFFECT; FORCED EXPIRATORY VOLUME; INHALATIONAL DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LUNG; META ANALYSIS; NEBULIZER; PATHOPHYSIOLOGY; PATIENT SELECTION; PRACTICE GUIDELINE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ANALYSIS OF VARIANCE; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; LUNG; MALE; NEBULIZERS AND VAPORIZERS; ODDS RATIO; PATIENT SELECTION; PRACTICE GUIDELINES AS TOPIC; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 79953259899     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-38     Document Type: Article

References (13)

1. Global strategy for asthma management and prevention. 2006, http://www.ginasthma.com
2. Global strategy for asthma management and prevention - updated. 2009, http://www.ginasthma.com
3. O'Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
4. Scicchitano R, Aalbers R, Ukena D, Manjra A, Fouquert L, Centanni S, Boulet LP, Naya IP, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004, 20:1403-1418. 10.1185/030079904X2051, 15383189.
5. Kuna P, Peters MJ, Manjra AI, Jorup C, Naya IP, Martinez-Jimenez NE, Buhl R. Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007, 61:725-736. 10.1111/j.1742-1241.2007.01338.x, 1920547, 17362472.
6. Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, Carlsheimer A. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007, 101:2437-2446. 10.1016/j.rmed.2007.07.014, 17905575.
7. Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006, 368:744-753. 10.1016/S0140-6736(06)69284-2, 16935685.
8. National Heart Lung and Blood Institute Guidelines for the Diagnosis and Management of Asthma. Expert Panel Report 3, National Heart Lung and Blood Institute., http://www.nhlbi.nih.gov/guidelines/asthma/asthsumm.pdf
9. Bateman ED, Reddel HK, Eriksson G, Peterson S, Ostlund O, O'Byrne PM. Overall asthma control - the relationship between current control and future risk. J Allergy Clin Immunol 2010, 125:600-608. 10.1016/j.jaci.2009.11.033, 20153029.
10. Bateman ED, Bousquet J, Busse WW, Clark TJ, Gul N, Gibbs M, Pedersen S. Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy 2008, 63:932-938. 10.1111/j.1398-9995.2008.01724.x, 18588561.
11. Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, Casale TB, Chanez P, Enright PL, Gibson PG, De Jongste JC, Kerstjens HA, Lazarus SC, Levy ML, O'Byrne PM, Partridge MR, Pavord ID, Sears MR, Sterk PJ, Stoloff SW, Sullivan SD, Szefler SJ, Thomas MD, Wenzel SE. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99. 10.1164/rccm.200801-060ST, 19535666.
12. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004, 170:836-844. 10.1164/rccm.200401-033OC, 15256389.
13. Sears MR, Radner F. Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials. Respir Med 2009, 103:1960-1968. 10.1016/j.rmed.2009.08.007, 19815402.